Howard S Hochster MD
@HH_Oncodr
Followers
1K
Following
155
Statuses
799
Rutgers-CINJ Associate Director for Clinical Research; Distinguished Prof RWJ Med School; Director Onc Research RWJBarnabas Health;
Rutgers-Cancer Inst of NJ
Joined March 2015
RT @RutgersCancer: This year on World Cancer Day 🌎 we will be "united by unique" with the Jack and Sheryl Morris Cancer Center. The Jack a…
0
3
0
RT @RutgersCancer: Clinical trials are vital for medical breakthroughs, yet Black and Hispanic patients represent only 4% of participants,…
0
4
0
👉Couldn’t agree more @jordanberlin5 ! 👉Actively mentoring and looking for junior investigators @RutgersCancer
While we had a great #ASCOGI25, I will say this again: It is a failure of mentorship when full professors are standing on the podium presenting new data. Time to make way for the next generation folks.
0
1
15
#GI25. Some practice changing trials presented today as illustrated by Dr Wells Messersmith. New options for molecular subsets by more to do for garden variety #coloncancer. Latest trials @RutgersCancer
0
7
20
#GI25 pre planned subset analysis of this phase 3 adjuvant colon cancer trial C80702. 👉👉Unexpected result that 3 yrs of celecoxib reduces recurrence in those ctDNA positive post op👈Thanks to Dr Meyerhardt and team! Latest trials @RutgersCancer
CtDNA blood test may help plan treatment and predict prognosis for patients with stage III #ColonCancer. Read a plain language summary of the research from #GI25:
0
2
12
Innovative biomarker driven trial in neoadjuvant Rx of #gastriccancer. Thanks to PIs Dr Tim Kennedy and Dr @SalmaJabbour1 @RutgersCancer @RWJBarnabas. Presented at #GI25. Thanks to all involved in this outstanding work and @Merck for support.
1
4
20
Interesting phase 3 data on intraperitoneal therapy from China #GI25 . Soon to be studied in @eaonc STOPGAP study. Study lead by Dr Brett Ecker @RutgersCancer soon
1
0
5
So honored to join @SWOG colleagues Kanwal Raghav, @skopetz and the other co-authors in publishing this key non-industry #Clinicaltrial showing benefit of HER2 directed Rx c/w chemo based Rx. Latest trials @RutgersCancer
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613) This randomized phase II trial evaluated the efficacy and safety of dual-HER2 inhibition (trastuzumab plus pertuzumab, TP) versus standard anti-EGFR therapy (cetuximab plus irinotecan, CETIRI) in patients with RAS/BRAF wild-type (WT), HER2-positive metastatic #ColorectalCancer (mCRC) as second or third-line treatment. The study included 54 participants, and while median progression-free survival (PFS) did not significantly differ between the groups (4.7 vs. 3.7 months), the efficacy of TP was strongly influenced by HER2 gene copy number (GCN). Patients with high HER2 amplification (GCN ≥20) had significantly longer PFS (9.9 vs. 2.9 months) and better objective response rates (57.1% vs. 9.1%) on TP compared to CETIRI. TP was also associated with fewer grade ≥3 adverse events (23.1% vs. 46.1%). Overall, TP demonstrated a safe and effective chemotherapy-free option for HER2-positive mCRC, with higher HER2 amplification predicting greater clinical benefit. @DrCrystalD
@mgfakih
@adasarimd
@SyedKazmiMD
@sepideh_gholami
@skopetz
@HH_Oncodr
@pashtoonkasi @CathyEngMD @marklewismd @AndresC27622123 @manjuggm @stacy_hurt @ARosen380 @KoheiShitara @GillSharlene @BenWestphalen
@heinrich_kat @Dr_Ivanoncologo
0
4
18
RT @OncoAlert: Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic…
0
15
0
RT @RutgersCancer: It's time for #MondaysAtTheMorris! The Jack & Sheryl Morris Cancer Center features 84 infusion bays, 74 exam rooms, adva…
0
3
0
Bravo to Dr Michael Kane and the 👉 entire stellar oncology pharmacy staff👈 @RutgersCancer - thanks for all you do to make our patients treatment safer and effective every day! 👏👏❗️
Today is National Pharmacist Day! 🌟 Flashback to when we visited our amazing @RutgersCancer Pharmacy Department! Thank you @RutgersCancer Pharmacy for all that you do to help take care of our patients. ❤️ @RWJBarnabas
0
0
1
@RutgersCancer @RWJBarnabas Annual Cancer Summit #CANCERNJ2024. Dr @RCLanganMD, Associate Chief Surgical Officer, informing us on exciting new AI technology for identifying pre-malignant pancreatic cysts
0
1
5
@RutgersCancer @RWJBarnabas Annual Cancer Summit #CANCERNJ2024. Dr George Raptis Northern Region Med Director and #breastcancer maven and Dr Sarah Schaefer expert surgeon discussing first case in this outstanding panel discussion.
0
1
4
@RutgersCancer @RWJBarnabas Annual Cancer Summit #CANCERNJ2024. Lu177 PRRT and #Neuroendocrine Cancer therapy, trials discussed by our experts Drs Matthew Deek and Brett Eckert.
0
0
6
@RutgersCancer @RWJBarnabas Annual Cancer Summit #CANCERNJ2024. Our fabulous Gynecologic Oncology team discussing state-of-the-art management of endometrial and ovarian cancer.
0
2
5
@RutgersCancer @RWJBarnabas #CANCERNJ2024 Summit Dr Sari Jacoby from Newark Beth Israel #sicklecell program discussing latest research and therapies. Amazing!
1
1
4
#CANCERNJ2024 Summit @RutgersCancer @RWJBarnabas Moderator @DrAEvens with Sharon Manne PHD outcomes researcher, Dr Peter Cole Dir Ped Oncology and Dr Louise Ligresti Director Survivorship. Great discussion
0
2
8
.@RutgersCancer @RWJBarnabas leadership has an insightful discussion on healthcare transformation at the @RutgersCancer Annual Oncology Clinical Practice and Research Summit. #CANCERNJ2024
@slibutti
0
0
3
#CANCERNJ2024 Summit. @RWJBarnabas @RutgersCancer Leaders @slibutti, Center Director, John Doll COO and Michael Prilutsky EVP for Northern Region. With moderator Susan Solometo, SVP for Oncology. Outstanding discussion of Healthcare Transformation
0
0
4
#CANCERNJ2024 Summit @RutgersCancer @rwj. Leaders of Oncology Service Line @SusanSolometo @slibutti and Michael Prilutsky discussing Healthcare Transformation. Thanks for your insights on challenges we are facing!
0
0
2